The paradox of clozapine in Black people with treatment-resistant schizophrenia

被引：0
作者：
Whiskey, Eromona [1 ,2 ]
Bachmann, Christian [3 ]
Dzahini, Olubanke [1 ,2 ]
Taylor, David [1 ,2 ]
Oloyede, Ebenezer [1 ,4 ]
机构：
[1] Maudsley Hosp & Inst Psychiat, Pharm Dept, London, England
[2] Kings Coll London, Inst Pharmaceut Sci, London, England
[3] Univ Hosp Ulm, Dept Child & Adolescent Psychiat, Ulm, Germany
[4] Univ Oxford, Dept Psychiat, Oxford, England
来源：
NATURE MENTAL HEALTH | 2025年 / 3卷 / 04期
关键词：
BENIGN ETHNIC NEUTROPENIA; UNTREATED PSYCHOSIS; MENTAL-HEALTH; RACIAL DISPARITIES; PRESCRIPTION PATTERNS; DURATION; PATHWAYS; DISCONTINUATION; CARE; SERVICES;
D O I：
10.1038/s44220-025-00411-9
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
Clozapine is currently the only licensed medication for treatment-resistant schizophrenia (TRS). Ethnic inequalities in treatment with clozapine have been described extensively, particularly regarding the effect on Black ethnic groups. Here we explore the reasons for clozapine underuse in this population, identifying potential misconceptions and providing suggestions to address these barriers.
引用
收藏
页码：402 / 407
页数：6
相关论文
共 85 条
  • [51] Moeller F G, 1995, Ann Clin Psychiatry, V7, P167, DOI 10.3109/10401239509149622
  • [52] Duration of untreated psychosis and ethnicity in the ÆSOP first-onset psychosis study
    Morgan, C
    Fearon, P
    Hutchinson, G
    McKenzie, K
    Lappin, JM
    Abdul-Al, R
    Morgan, K
    Dazzan, P
    Boydell, J
    Harrison, G
    Craig, T
    Leff, J
    Jone, P
    Murray, R
    [J]. PSYCHOLOGICAL MEDICINE, 2006, 36 (02) : 239 - 247
  • [53] Pathways to care and ethnicity. 2: Source of referral and help-seeking - Report from the AESOP study
    Morgan, C
    Mallett, R
    Hutchinson, G
    Bagalkote, H
    Morgan, K
    Fearon, P
    Dazzan, P
    Boydell, J
    McKenzie, K
    Harrison, G
    Murray, R
    Jones, P
    Craig, T
    Leff, J
    [J]. BRITISH JOURNAL OF PSYCHIATRY, 2005, 186 : 290 - 296
  • [54] Active monitoring of 12760 clozapine recipients in the UK and Ireland - Beyond pharmacovigilance
    Munro, J
    O'Sullivan, D
    Andrews, C
    Arana, A
    Mortimer, A
    Kerwin, R
    [J]. BRITISH JOURNAL OF PSYCHIATRY, 1999, 175 : 576 - 580
  • [55] Worldwide Differences in Regulations of Clozapine Use
    Nielsen, Jimmi
    Young, Corina
    Ifteni, Petru
    Kishimoto, Taishiro
    Xiang, Yu-Tao
    Schulte, Peter F. J.
    Correll, Christoph U.
    Taylor, David
    [J]. CNS DRUGS, 2016, 30 (02) : 149 - 161
  • [56] Predictors of Clozapine Response in Patients With Treatment-Refractory Schizophrenia Results From a Danish Register Study
    Nielsen, Jimmi
    Nielsen, Rene Ernst
    Correll, Christoph U.
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2012, 32 (05) : 678 - 683
  • [57] Ethnic variations in duration of untreated psychosis: report from the CRIS-FEP study
    Oduola, Sherifat
    Craig, Tom K. J.
    Morgan, Craig
    [J]. SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY, 2021, 56 (06) : 931 - 941
  • [58] Identifying clinically relevant agranulocytosis in people registered on the UK clozapine Central Non-Rechallenge Database: retrospective cohort study
    Oloyede, Ebenezer
    Bachmann, Christian J.
    Dzahini, Olubanke
    Alcaraz, Juan Miguel Lopez
    Singh, Shaurya Dev
    Vallianatu, Kalliopi
    Funk, Burkhardt
    Whiskey, Eromona
    Taylor, David
    [J]. BRITISH JOURNAL OF PSYCHIATRY, 2024, 225 (05) : 484 - 491
  • [59] The lived experience of clozapine discontinuation in patients and carers following suspected clozapine-induced neutropenia
    Oloyede, Ebenezer
    Dunnett, Danielle
    Taylor, David
    Clark, Ivana
    MacCabe, James H.
    Whiskey, Eromona
    Onwumere, Juliana
    [J]. BMC PSYCHIATRY, 2023, 23 (01)
  • [60] What are the barriers and facilitators of clozapine use in early psychosis? A survey of UK early intervention clinicians
    Oloyede, Ebenezer
    Blackman, Graham
    Mantell, Bethany
    Harris, Eleanor
    Williams, Julie
    Taylor, David
    MacCabe, James
    McGuire, Philip
    [J]. SCHIZOPHRENIA, 2023, 9 (01)
123456789